AMPK has been proposed as an attractive drug target for the treatment of metabolic diseases which has led to great interest in the development of isoform selective compounds [69], such the allosteric activator of α1-containing heterotrimeric complexes C2 [70]. This evidence concerns the gene PRKAA1 and metabolic disease.